SBIR/STTR Research Award
Nano-Antibodies for Studying RNA Modifications
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- VL99GKFNM1G3
- Solicitation number
- DA15-001
- Topic code
- NIDA
Research abstract
DESCRIPTION (provided by applicant): The goal of the proposed Phase I research is to develop a set of commercial reagents for recognizing 2'-O-methyladenosine (Am), 2'-O-methylcytidine (Cm), 2'-O-methylguanosine (Gm) or 2'-O-methyluridine (Um), as well asindiscriminately to all four 2'-O-methyl ribose moiety. The core technologies that serve as the foundation of these new reagents are based on the unique properties of camelid antibodies, which have been well accepted as valuable binding reagents for proteins and haptens, but so far without any example for RNA modifications. The main advantage of the proposed single-domain (VHH) antibodies from camelidae is that they have very high affinity and specificity, and they are easy to reproduce as monoclonal antibodies, stable, and of very small size, enabling super-resolution imaging when conjugated to dye. Currently, affinity reagents of any type are only available for monitoring a handful among the more than 100 RNA modification moieties. The best examples o
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Effective Nanoantibodies as Promising Therapeutics for Treating Sepsis
- Human Neural Stem Cells Engineered against oAβ Induced Toxicity for Cell Therapy
- Adaptable and Automated Large-Scale Manufacturing of iPSC-Derived Cell Products
- Anti-RPS23RG1 Nanoantibody as Novel Therapeutic and Research Reagents for Alzheimer’s Disease.
- Generation and Characterization of Nanobodies Against beta-Amyloid
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)
Research funding history
17 SBIR/STTR records share this UEI (2001–2018). Reported award amounts total $3,047,648. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services